The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line gemcitabine, oxaliplatin, and l-asparaginase chemotherapy followed by involved field radiation in stage IE/IIE extranodal NK/T-cell lymphoma.
Z. j. Xia
No relevant relationships to disclose
Z. h. Wang
No relevant relationships to disclose
S. Li
No relevant relationships to disclose
X. q. Chen
No relevant relationships to disclose
F. h. Wang
No relevant relationships to disclose
F. Xu
No relevant relationships to disclose
N. n. Zhou
No relevant relationships to disclose
Y. Xia
No relevant relationships to disclose
Y. j. Li
No relevant relationships to disclose
K. f. Wang
No relevant relationships to disclose